

Seconda Lezione: Interpretare il dolore

14 / 03 / 2018



Sorrow, 1882
V. Van Gogh

Levis est dolor qui loquitur, magnus muta

Lieve è il dolore che parla...Il grande dolore è muto.



Lucio Anneo Seneca (Corduba 4 a.C. – Roma 65 d. C)

Pain

“An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”

IAPS, APS, 2003

- Pain is always a subjective experience;
- Everyone learns the meaning of “pain” through experiences (usually injuries) in early life;
- Pain is a significant cause of stress

Various types of pain

Somatic pain: caused by the activation of pain receptors in the skin or deeper tissues (musculoskeletal tissues)

Visceral pain: caused by activation of pain receptors (e.g., infiltration, compression, stretching) of the thoracic, abdominal or pelvic viscera

Neuropathic pain: caused by injury to the nervous system (e.g., a tumor compressing nerves or the spinal cord, or cancer actually infiltrating into the nerves or spinal cord)

Acute vs. chronic pain

Acute pain:

- short-lasting (up to 'several days')
- clinically associated with diaphoresis and tachycardia
- increasing in intensity over time, or it can occur intermittently (**episodic or intermittent pain**)
- usually related to a discreet event for onset: e.g., post-operative, post-trauma, etc...

Chronic pain:


- long-term (> 3 months)
- more subjective (less characterized than acute pain)
- more commonly associated with psychological distress
- usually affects a patient's quality of life

Pain: How do we measure it ?




zero

max



General features


Somatic and visceral pain pathways




(a) Dorsal column–medial lemniscal pathway

(b) Spinothalamic tract


Processing of Sensory Signals in Spinal Cord, Brain Stem, and Brain




Ascending Visceral Pain Pathway




Descending Pain Modulation



Convergence of Somatic and Visceral Afferents in the Spinal Cord




Divergence of Somatic and Visceral Afferents in the Spinal Cord




(Wolf et al. 1965)

Mackenzie's Interpretation of the mechanisms of visceral pain and related reflexes (1909)





Colonic Referred Pain



→  Increased pain intensity


Mechanism(s) of visceral pain

Pathways of visceral sensations




rIGLEs

Low-threshold vagal mechanoreceptor




Muscular-mucosal afferents

Types of afferents in the gut




Vascular / mesenteric afferents act as nociceptors of the gut

Nociceptors
(vascular / mesenteric
afferents)




- Many are 'silent nociceptors'
- Modulated by inflammation
- Activation evokes vasodilation



Feng B & Gebhart GF, *Am J Physiol* 2011; 300:G170-180

Song X et al., *Gastroenterology* 2009; 137:274-284



Visceral hypersensitivity evoked by serosal (splanchnic) afferents in a mouse model of colitis



- Low-threshold mechanosensory fibers → not involved
- High-threshold (nociceptors) → acute and chronic (recovery) hypersensitivity


Hypersensitivity in the clinical setting

Visceral hypersensitivity in IBS




Whitehead W.E., et al., *Dig Dis Sci* 1980; 25(6):404-1


Repetitive Stimulation Sensitizes the Spinal Cord



Prevalence of rectal hypersensitivity in IBS




Female with IBS show more hypersensitivity than male pts




*Posserud I., et al., Gastroenterology
2007;133: 1113-23*

Altered perception is associated with symptom severity in IBS




Mechanisms and sites of hypersensitivity



Mechanisms of visceral hypersensitivity



Mechansims of Altered Afferent Sensitivity






Increased TRPV1-immunoreactive sensory fibres in IBS



- 23 IBS pts; ~ 2/3 with non-D-IBS
- Low-grade inflammation
- Only TRPV1-IR nerves and MCs correlated with pain

Colonic mucosal mediators of IBS patients excite rat mesenteric sensory neurons



Proteases mainly involved in the firing of sensory neurons in IBS

CNS: visceral hypersensitivity



actual rectal distension (45 mmHg)



expectation rectal distension

IBS hypersensitive
(n=15)

IBS normosensitive
(n=18)

controls
(n=18)




 fMRI activation
 fMRI deactivation

↑ activation insula & ACC in hypersensitive vs normosensitive & controls

↑ activation insula in hypersensitive vs normosensitive

↑ activation right hippocampus in normosensitive vs controls

Visceral and somatic hypersensitivity overlap in IBS pts




**IBS pts 2fold ↑
of somatic comorbidities
e.g. fibromyalgia, CFS, etc.**

*Riedel A., et al., J Psychosom Res
2008;64:573-582*


Mechanoreceptors of the Digestive tract - localisation

Vascular
(8/10 high threshold)




Tonic & Phasic distensions

Mucosal
(8/10 low threshold)



Phasic Distension
(act in parallel)




Serosal
(1/3 low threshold)



Tonic Distension
(act in series)


Possible sites of alterations in gut sensitivity




Spinal Gating for Three Classes of Visceral Nociceptors (Low, High and Silent) Account for Normal Regulatory Functions, Acute and Chronic Pain


Synaptic terminal, second order, active neuron

Synaptic terminal, spinal and inactive neuron





Pharmacological treatment



Non-opioid antinociceptive drugs

Opioid drugs

Non-opioid antinociceptive drugs

Drug	Dose (mg)	Frequency of administration
Paracetamol (acetaminophen)	1000	Every 6-8 hours
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprophen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
Selective COX-2 inhibitors		
• Celecoxib	200	Every 12 hours
• Etoricoxib	120	Once a day

Paracetamol

- First choice in mild-moderate pain

Dose:

1 g x 4 / day

Hepatopathy / altered hepatic function:


1 g x 3 / day

- No cross-reaction with NSAIDs

NSAIDs

Drug	Dose (mg)	Frequency of administration
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprophen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
Selective COX-2 inhibitors <ul style="list-style-type: none"> • Celecoxib • Etoricoxib 	200 120	Every 12 hours Once a day

Mechanisms of action of NSAIDs



NSAIDs

- Pain related to inflammation

- DICLOFENAC: no antiplatelet action
- IBUPROFEN: lowest gastrolesivity
- KETOROLAC: highest gastrolesivity

Non-opioid antinociceptive drugs

Drug	Dose (mg)	Frequency of administration
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprophen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
Selective COX-2 inhibitors		
• Celecoxib	200	Every 12 hours
• Etoricoxib	120	Once a day




PPIs to prevent
gastropathy



PPIs not strictly
necessary;
cautiously
administered
in pts with
previous CAD




Thomas Sydenham (1624-1689)




Among the remedies which it has pleased Almighty God to give to man to relieve his sufferings, none is so universal and so efficacious as opium...

Opioid use and prescriptions

Increased use of opioids



Indications for opioid prescribing



- In 2012, >240 million prescriptions for opiate analgesics in the USA
- ~40-80% of pts take opioids for chronic, non-cancer pain
- Up to 94% of patients with advanced illness who take opioids require laxatives
- Standard laxatives are often insufficient for treatment of OIC and fail in ≈50% of cases

Camilleri M., *Am J Gastroenterol.* 2011;106(5):835-42; IMS Health 2012 (reported by Fauber J. J Sentinel. March 6, 2013);

Holzer P., *Eur Rev Med Pharmacol Sci.* 2008; 12 (S1): 119-127;6

Opioid System

- Endogenous opioids:

- Dynorphins
- β endorphins
- Enkephalins



Receptors:

- μ
- δ
- κ
- σ

CNS

PNS

ENS



- Effects:

- Euphoria
- Analgesia
- Sedation
- Relief from diarrhea
- Cough suppression

- Localization & Function in the ENS:

- Enteric neurons
- Smooth muscle cells
- Immune cells
- GI motility & secretion
- Immune response

Opioids

Opioid	Half life (h)	Onset (h)	Duration (h)	Relative potency	Initial dose (mg)	Dosing interval (h)
Pethidine / Meperidine (Demerol)	2-3	0.1-0.4	1-3	0.1	50-150	4
Codeine	3	0.25-1.0	3-4	0.15	30-60	4
Hydromorphone (Jurnista)	2-3	0.3-0.5	2-3	4	2-4	4
Oxycodone (Oxycontin)	2-3	0.5	3-6	1.5	5-10	6
Methadone (Dolophine, Eptadone)	15-30	0.5-1.0	4-6	3	20	6-8
Propoxyphene (Darvon, Darvocet)	6-12	1.0-2.0	3-6	0.15	100	6
Tramadol (Contramal, Ultram)	6-7	1.0-2.0	3-6	0.1	50	4-6
Morphine solution (Oramorph)	2-4	0.5-1.0	4	1	10	3-4
Morphine controlled release (MS Contin)	2-4	1.0	8-12	1	15	8-12
Fentanyl (Durogesic)	1-6	12-24	48-72	100	0.025-0.050/hr	48-72

Paracetamol + Codeine

- Mild-moderate pain or severe pain (with contraindications for NSAIDs)
- Possible use in association with major analgesic drugs
- Up to 10% of population are poor metabolizers (i.e., little / no analgesia from codeine)
- Rapid metabolizers also may have little analgesic effect

Dose adults / children > 40 kg:

500-30 mg/6 h – 1000 mg-60 mg/8 h (max 3g-180mg)

Dose children 30-40 kg:

500 mg-30 mg /8 h

Morphine

- 10 mg / mL vials for i.v. administration
- Peak in 5 min; half-life: 10 min

Dose adults / children:

1° bolus: 0.1 mg / kg

2° bolus (after 10 min): 0.05 mg / kg

Dose elderly-renal insufficiency-hepatic insufficiency:

1° bolus: 0.05 mg / kg

2° bolus (after 10 minuti): 0.0025 mg / kg

- Oral morphine (tablets): 10 – 30 – 60 – 100 mg PR / oral solution: 10 – 30 – 100 mg / 5 mL
- Histamine release !

Fentanyl-1

- 0.1 mg / 2 mL vials for i.v. administration; rapid onset and very short half-life
- Peak in 5 min; half-life: 10 min

Dose (i.v. = intranasal; adults = children),

NO ADJUSTMENT IN HEPATIC OR RENAL INSUFFICIENCY:

1° bolus: 1.5 mcg / kg

2° bolus (after 10 min): 0.75 mcg / kg

Dose in the elderly:

1° bolus: 0.75 mcg / kg

2° bolus (after 10 min): 0.35 mcg / kg

- Side effects → avoidable with administration of a rapid bolus diluted in 0.9% saline solution

Fentanyl-2

- Transdermal patch for constant analgesia
- Transdermal patch 12 mcg / h – 25 mcg / h – 50 mcg / h – 75 mcg / h - 100 mcg / h
- Titration with adjustment of 12 / 25 mcg / h - change patch every 72 h

Oral Morphine 24 h (mg/day)	Fentanyl t-dermal patch dose (mcg/h)
< 44	12
45 - 89	25
90 - 149	50
150 - 209	75
210 - 269	100
270 - 329	125
330 - 389	150
390 - 449	175
450 - 509	200
510 - 569	225
570 - 629	250
630 - 689	275
690 - 749	300

Oxycodone

- Oral administration (dosing interval 12 h)
- Tablets 5 - 10 - 20 - 40 - 80 mg

Initial dose: 5 mg x 2 / day + on demand therapy with oral morphine (Oramorph 10 mg) max 4 / day

- Dose adjustment (5 mg) every 24 h if need for Oramorph > 2 / day
- 10 mg oral oxycodone = 20 mg oral morphine


Tolerance and dependence

Tolerance

- Pharmacologic effect characteristic of opioids
- With regular use, opioids become less effective over time and tolerance develops
- Tolerance does not develop to pupil constriction and constipation
- Higher dose are needed to achieve the same effect

Dependence

- Development of physiological / psychological adaptation in response to long term use
- A chronic , relapsing condition associated with physical changes in the brain due to frequent use
- Experience cravings and withdrawal symptoms when the effects of opioids begin to wear off



Side effects

Acute opioid intoxication/overdose

Signs and symptoms

Disruption of central control of peripheral sympathetic activity

Respiratory depression → apnea

Circulatory depression → hypotension

Constricted pupils (maybe dilated with meperidine)

Convulsions with meperidine and propoxyphene

Arrhythmias with propoxyphene

Pulmonary edema

Reduced reflexes

CNS depression

Drowsiness → sedation → coma

Treatment



Naloxone

0.4 mg intravenously and repeated as necessary

Short duration of action, 1-2hrs


Give every 30mins until patient is stable

Opioid induced bowel dysfunction




PEG / Macrogol: (Almost) All you wanted to know in...

↓ transit
(> left vs. right colon)



Corazziari E.S., et al., *Dig Dis Sci*
1996; 41:1636-42

Global, long-term
efficacy in constipation




Ford AC & Suares NC.,
Gut 2011;60:209-218

Binding water
=
Iso-osmotic effect



Schiller L.R., et al.,
Gastroenterology 1988;94:933-41



1st line-therapy in many
patient subtypes




De Giorgio R., et al.,
Eur Rev Med Pharmacol Sci 2011;
15:960-66

No major adverse events

Well tolerated
(bloating, flatulence
may occur)

Corazziari E.S., et al.,
Gut 2000; 46: 522-526

PEG no electrolytes =
PEG + electrolytes




Seinela L., et al.,
Drugs Aging 2009; 26:703-13

Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)

Currently available therapeutics:

Methylnaltrexone (6 trials)*; Alvimopan (4 trials); Naloxone (4 trials); Naloxegol (2 trials)

- Antagonize peripheral constipating effect of opioids
- Restricted ability to cross BBB
- No effect on analgesia



for review see: Camilleri M., et al., Neurogastroenterol Motil 2014;26(10):1386-95


* FDA approved


Types of available prokinetics


Drug	D ₂ antag	5-HT ₄ ago	5-HT ₃ antag	Colinest Inib.	Mot R ago	Dominant Effect(s)
Anticholinesterases						
Neostigmine	-	-	-	+++	-	GI prokinetic
Pyridostigmine	-	-	-	+++	-	
Antidopaminergic*						
Domperidone	+++	-	-	-	-	Antiemetic; prokinetic (UGI)
Antidopaminergic** serotonergic						
Metoclopramide	+++	+	+	-	-	Antiemetic; prockinetic (UGI)
Sulpiride	+++	+	±	-	-	Antiemetic; prokinetic (UGI)
Clebopride	+++	?	?	-	-	Antiemetic; prokinetic (UGI)
Itopride	+++	-	-	++	-	Prokinetic (UGI)
Serotonergic						
Prucalopride	-	+++	-	-	-	Enterokinetic


* Butyrophenone derivatives; ** Benzimidazole derivatives


WHO pain ladder























Il valore dell'anamnesi (ανά μνήσις)...ma quale anamnesi ?

- **Anamnesi patologica prossima:**

Motivo del ricovero in PS, Reparto, della visita ambulatoriale, etc

Non sempre facile stabilire una netta separazione tra APR e APP...
(sintomi direttamente riconducibili alla patologia pregressa)

Sintomi !!!! Fondamentale chiedere: quando ?
come ? Acutamente o più gradualmente ?
caratteristiche ? Continuo...o periodico ?
intensità ?
è in relazione con atti fisiologici ? Postura ?

Se il sintomo è il «dolore»: sede, irradiazione, caratteri, tipologia
quando è comparso ? A digiuno ? Dopo
aver mangiato

C'è febbre ?

Acute pain

- **AMI**
- **Trigeminal nevralgia**
- **Migraine**
- **Renal colic**
- **Herpes zooster (VZV)**